Health
Ozempic Shows Promise Treating Kidney Failure in Blow to Dialysis Firms
- Treatment meets pre-criteria set by committee for efficacy
- Study raises concern about future demand for kidney dialysis
Ozempic
Photographer: Mario Tama/Getty ImagesThis article is for subscribers only.
Novo Nordisk A/S diabetes drug Ozempic showed surprisingly early effectiveness in a kidney-failure study, sending shares of the world’s biggest dialysis providers tumbling.
An independent data monitoring committee recommended halting the study after an interim analysis showed the drug hit an efficacy goal, Novo said late on Tuesday. The Danish drugmaker will get full results of the study once the process of closing it is complete. That’s expected by the first half of 2024.